Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data by Hemilä, Harri & Chalker, Elizabeth




DOI: 10.1002/prp2.810  
O R I G I N A L  A R T I C L E
Carrageenan nasal spray may double the rate of recovery from 
coronavirus and influenza virus infections: Re- analysis  
of randomized trial data
Harri Hemilä1  |   Elizabeth Chalker2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for 
Pharmacology and Experimental Therapeutics.
Abbreviations: CI, confidence interval; IPD, individual- patient data; NNT, number needed to treat; RCT, randomized trials; RR, risk ratio.
1Department of Public Health, University 
of Helsinki, Helsinki, Finland
2School of Public Health, University of 
Sydney, Sydney, Australia
Correspondence
Harri Hemilä, Department of Public 
Health, University of Helsinki, POB 41, 





In this individual patient data meta- analysis we examined datasets of two randomized 
placebo- controlled trials which investigated the effect of nasal carrageenan sepa-
rately on children and adults. In both trials, iota- carrageenan was administered na-
sally three times per day for 7 days for patients with the common cold and follow- up 
lasted for 21 days. We used Cox regression to estimate the effect of carrageenan on 
recovery rate. We also used quantile regression to calculate the effect of carrageenan 
on colds of differing lengths. Nasal carrageenan increased the recovery rate from all 
colds by 54% (95% CI 15%– 105%; p = .003). The increase in recovery rate was 139% 
for coronavirus infections, 119% for influenza A infections, and 70% for rhinovirus in-
fections. The mean duration of all colds in the placebo groups of the first four quintiles 
were 4.0, 6.8, 8.8, and 13.7 days, respectively. The fifth quintile contained patients 
with censored data. The 13.7- day colds were shortened by 3.8 days (28% reduction), 
and 8.8- day colds by 1.3 days (15% reduction). Carrageenan had no meaningful effect 
on shorter colds. In the placebo group, 21 patients had colds lasting over 20 days, 
compared with six patients in the carrageenan group, which corresponds to a 71% 
(p = .003) reduction in the risk of longer colds. Given that carrageenan has an effect 
on diverse virus groups, and effects at the clinical level on two old coronaviruses, it 
seems plausible that carrageenan may have an effect on COVID- 19. Further research 
on nasal iota- carrageenan is warranted.
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1  |  INTRODUC TION
Carrageenan is a sulfated polysaccharide extracted from red sea-
weed,	 commonly	 known	 as	 Irish	Moss.1– 3 Since the 1980s, carra-
geenan has been shown to prevent infections due to several viruses 
in cell cultures, including influenza viruses, coronavirus OC43, rhi-
noviruses, and coxsackievirus.4– 11 A few very recent studies showed 
that carrageenan can inhibit the replication of the SARS- CoV- 2 
virus.12– 15	Mortality	of	mice	infected	by	influenza	A15– 17 and by her-
pes simplex18 was significantly decreased by mucosally administered 
carrageenan, which indicates that the effects on respiratory viruses 
are not limited to cell cultures.
Carrageenan has been used as a food component for decades 
and is classified by the FDA as “generally regarded as safe” [GRAS].19 
Many	 concerns	 about	 potential	 harms	 of	 carrageenan	 have	 been	
shown to be unfounded and are explained, for example, by confus-
ing carrageenan with polygeenan and using inappropriate biological 
model systems.19– 21 A recent review concluded that animal studies 
have found dietary carrageenan to be safe in that it is not a car-
cinogen or tumor promoter, nor does it have developmental, repro-
ductive, or genotoxic effects.19 The European Food Safety Authority 
states that “no adverse effects have been detected in chronic toxic-
ity studies with carrageenan in rats up to 7500 mg/kg bw per day”.22 
For a 70 kg person, this corresponds to 525 g per day. A recent study 
with mice and rabbits indicated that nasal and pulmonary adminis-
tration of iota- carrageenan did not cause acute adverse effects.23
Three randomized trials (RCT) with adults24– 26 and one trial with 
children27 found that nasally administered iota- carrageenan short-
ened and alleviated common cold symptoms. The carrageenan dose in 
these trials was 0.001 g/day administered nasally for about one week 
and so potential concerns about very high oral doses for decades are 
not pertinent. An individual- patient data (IPD) meta- analysis pooled 
the results of one adult trial25 and the child trial,27 for which cold 
duration data were available, and concluded that there was evidence 
that iota- carrageenan shortened colds caused by coronaviruses 
OC43 and 229E, influenza A virus, and rhinoviruses.28 The mean du-
ration of all virus- positive colds was reported to be 1.9 days shorter 
in the iota- carrageenan groups.28 However, several patients did not 
recover by the end of the follow- up and therefore the mean duration 
is not an appropriate measure of effect. Furthermore, when assessing 
the effects of interventions on common cold duration, relative effect 
estimates such as percentages are preferable to days shortened.29 In 
this reanalysis of the IPD of the two trials25,27 we estimate the effect 
of carrageenan on the common cold using survival analysis and quan-
tile regression, both of which are not limited by some patients not 
recovering during the follow- up period.
2  |  MATERIAL S AND METHODS
The Ludvig trial with adults25 and the Fazekas trial with children27 are 
described in detail in the trial reports. In brief, both trials were rand-
omized, double- blind, placebo- controlled trials, carried out in Vienna, 
Austria. For enrollment, participants were required to have mild to 
moderate common cold symptoms and the duration of colds was not al-
lowed to be longer than 48 h for adults,25 and 36 h for children.28 In both 
trials, the randomization list was prepared by a third party and patients 
were randomly assigned using a permuted block schedule (size four).28 
The carrageenan spray and the placebo spray were indistinguishable. A 
single dose of 0.14 ml of nasal spray (0.12% iota- carrageenan) was ad-
ministered to both nostrils three times per day for 7 days in both trials. 
Thus, the total daily dose of iota- carrageenan was 1.0 mg.
The biological effect of carrageenan appears to prevent the 
virus from binding to cell surfaces or penetrating the cells,1– 3 so the 
pooled IPD analysis28 was limited to virus- positive participants. In 
the Ludvig trial, 59 of 102 participants in the carrageenan group and 
59 of 101 participants in the placebo group were virus positive.25 
In the Fazekas trial, 67 of 76 participants in the carrageenan group 
and 69 of 77 participants in the placebo group were virus positive.27 
Thus, the proportion of participants who were virus positive was 
very similar in the treatment arms within both trials.
Survival curves for the combined IPD of all virus- positive partici-
pants in the two trials25,27 were published as figure 2 in the previous 
meta- analysis.28 Survival curves for the colds caused by coronavi-
ruses OC43 and 229E, influenza A virus, and rhinoviruses were pub-
lished in figure 5 of Ref. [28]. Figures 2 and 5 of Ref. [28] reported 
intention- to- treat [ITT] and per- protocol data. Since the ITT analysis 
is generally preferable,30,31 we used the ITT data for infected partic-
ipants in our estimation of the carrageenan effect.
To regenerate the dataset, we downloaded the two figures and 
measured the height of the steps in the ITT curves using a graphics 
program and transformed the step heights to the number of patients 
who recovered on each day during the follow- up (see details in the 
Supplement). There were problems in regenerating the data from 
the curves for rhinovirus colds, but these were resolved after receiv-
ing data from Dr. Eva Prieschl- Grassauer. The rate of recurrence of 
colds was calculated from figure 3 of Ref. [28] for all colds, and from 
figure 6 of Ref. [28] for the virus- specific data.
What is already known about this subject
-	 Mucosally	 administered	 carrageenan	 has	 decreased	
mortality of mice infected by influenza A and by herpes 
simplex.
- Laboratory studies have indicated that carrageenan can 
protect against SARS- CoV- 2 in cell cultures.
- Four RCTs have indicated that nasal iota- carrageenan 
may alleviate common cold symptoms.
What this study adds
- Nasal carrageenan increased the recovery rate of coro-
navirus, influenza A, and rhinovirus infections.
- Quantile treatment effect appears a useful measure of 
treatment effects on the duration of infections.
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In this study, we analyze two outcomes28: (1) duration of the com-
mon cold defined as the time until the last day with common cold 
symptoms and (2) recurrence of common cold symptoms after the 
patient reported having been without symptoms for at least 1 day.
We used two approaches to estimate the effect of iota- 
carrageenan on common cold duration: survival analysis and quan-
tile regression. We used the coxph procedure of the survival package 
of the R- project to calculate the risk ratio (RR) for the recovery from 
the common cold and its 95% confidence interval (CI).32,33 For ties, 
we used the exact option, except for time- dependent survival analy-
sis, for which we used the Efron option. We used the likelihood ratio 
test to calculate the P- value for the effect of carrageenan.
We also used quantile regression to analyze quantile treatment 
effects.34– 36 A similar approach was recently used to analyze the 
therapeutic effect of vitamin C on SARS- Cov- 2 infection.37 Since 
there were censored data, we used the crq procedure of the quantreg 
package of R to calculate the 95% CI for the quantile treatment ef-
fect for 80th percentile level using the PengHuang option.35,36 To 
estimate the effect of carrageenan on the mean duration of colds 
within quintiles of the duration distribution, we calculated the mean 
durations for the 1st to 4th quintiles, but not for the 5th quintile be-
cause the last included the censored observations. To estimate the 
effect of carrageenan on the mean duration within the quintiles, we 
calculated the days shortened as the difference between the mean 
durations, and we also calculated the corresponding effect in per-
centages, which has been shown to be a superior measure compared 
with the absolute difference in days.29
To calculate the risk ratio (RR) for the occurrence of long colds 
(>20 days) and for the recurrence of cold symptoms after the pa-
tient had been without symptoms, and their 95% CI, we used the 
riskratio procedure of the fmsb package.38 We present two- tailed 
p- values. See supplementary file for printouts of the statistical 
calculations.
3  |  RESULTS
In our analysis, we used the pooled IPD from two iota- carrageenan 
randomized trials.25,27 The mean ages of participants in the trials 
were 5 years27 and 33 years25 and the sex of participants was rela-
tively balanced in both trials. In the iota- carrageenan groups of the 
two trials, there were 126 common cold patients with virus- positive 
colds, and in the placebo groups there were 128 participants.
Participants who received nasal carrageenan had a recovery rate 
greater than those who received placebo with RR = 1.54 (Figure 1A). 
Separate recovery data were available for coronaviruses OC43 or 
229E, influenza A virus, and rhinoviruses. The reproduced survival 
curves for these three virus groups are shown in Figure 1B– D. 
Carrageenan increased the recovery rate from coronavirus infec-
tions by RR = 2.39, from influenza A infections by RR = 2.19, and 
from rhinovirus infections by RR = 1.70 (Table 1). The confidence in-
tervals for the three virus groups are widely overlapping, indicating 
that the findings for all the three virus groups are consistent given 
the inaccuracy of the findings.
F I G U R E  1 The	effect	of	nasal	
iota- carrageenan on the recovery from 
common cold episodes caused by any 
virus (A), coronavirus OC43 or 229E (B), 
influenza A (C), and rhinovirus (D). The 
ITT survival curves published in figures 
2 and 5 of Ref. [28] were measured and 
datasets were regenerated for the current 
analysis; see the Supplementary file. In 
the curves of the figure, the size of the 
steps downwards indicates the number of 
patients who recovered on the particular 
day. The red horizontal dotted lines 
indicate the 20th, 40th, 60th, and 80th 
percentiles of the distribution of common 
cold duration, starting with the shortest 
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For all the virus- positive colds combined, the pattern of the sur-
vival curves indicates different effects of carrageenan on short and 
long colds (Figure 1A). Over the first 5 days, the recovery rate was 
very similar in the carrageenan and placebo groups with RR = 0.98 
(95% CI 0.55– 1.73), but during the follow- up from day 6 onwards, 
carrageenan increased the recovery rate by RR = 1.64 (95% CI 1.22– 
2.2; p = .001).
The treatment effect of carrageenan was also analyzed with 
quantile regression, in which the distribution of common cold 
duration is set on the horizontal axis as percentiles (Figure 2). 
The continuous black line shows the carrageenan treatment ef-
fect by the percentile levels. The effect of carrageenan is seen to 
be heterogeneous. The red dotted line indicates the null effect 
level and the blue dashed line shows the previously calculated 
effect estimate of 1.9 days,28 which exaggerates the effect of 
carrageenan for short colds, but underestimates the effect for 
F I G U R E  2 The	quantile	treatment	effect	of	nasal	iota-	
carrageenan on the duration of virus- positive colds as days 
shortened. The horizontal axis shows the distribution of the 
duration of colds by percentiles for up to the 83th percentile, after 
which data in the placebo group was censored, that is, patients 
did not recover by the end of the follow- up. The red dotted line 
indicates the null effect level, and the blue dashed line shows the 
previously calculated 1.9- day estimate of effect for carrageenan.28 
The red figures at the bottom indicate the lowest percentile level 
for the indicated common cold duration in the placebo group. For 
example, 9- day colds cover the percentile range from 43.0 to 60.9 
percentiles, which corresponds to 21 patients as the total number 
of placebo group patients was 128. The red vertical bar indicates 
the 95% CI of the treatment effect for the 80th percentile
F I G U R E  3 The	quantile	treatment	effect	of	nasal	iota-	
carrageenan on the duration of virus- positive colds as a relative 
effect in percentages. The horizontal axis shows the distribution of 
the duration of colds by percentiles from the 60th up to the 83th 
percentile, after which data in the placebo group were censored, 
that is, 21 patients in the placebo group did not recover by the end 
of the follow- up
TA B L E  2 Effect	of	iota-	carrageenan	on	common	cold	duration	
by quintiles of the cold distribution
Quintile






1. 3.80 4.04 0.24 5.9%
2. 6.56 6.81 0.25 3.6%
3. 7.52 8.84 1.32 14.9%
4. 9.84 13.69 3.85 28.1%
The 5th quintile range is not shown since it contains the participants 
with censored data. The relative scale (percentage shortened) has been 
shown to be more informative in the analysis of effects on duration.29
Viruses
Number of patients Effect of iota- carrageenan
Carrageenan Placebo RR (95% CI) p
All virusesa  126 128 1.54 (1.15– 2.1) .003
Coronavirus OC43 or 229E 45 43 2.39 (1.43– 4.0) .001
Influenza A 23 24 2.19 (1.12– 4.3) .021
Rhinovirus 70 80 1.70 (1.17– 2.5) .006
RR, risk ratio of recovery comparing iota- carrageenan versus placebo groups.
aIn addition to the three virus groups listed, the “all viruses” group includes patients with influenza 
B, parainfluenza, respiratory syncytial virus, and metapneumovirus. A few patients had two or 
more viruses.
TA B L E  1 Effect	of	iota-	carrageenan	
on the rate of recovery from the common 
cold
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long colds. All percentiles from 0 to 43 had an effect estimate 
below 1.9 days, whereas all percentiles from 71 to 83 had an ef-
fect estimate above 1.9 days. Thus, over half the observations 
appear inconsistent with the calculated 1.9- day effect.28 In the 
80th percentile of patients in the placebo group, colds lasted for 
19 days and iota- carrageenan shortened them by 7 days (95% CI 
10.6– 2.9 days; p = .001). This corresponds to a 37% shortening 
of colds at the 80th percentile level. The vertical bar shows the 
95% CI for the 80th percentile point, which is far from the 1.9- day 
estimate (Figure 2).
Figure 3 shows the quantile treatment effect on the relative 
scale, which adjusts for the variation in the duration in the placebo 
group.29 Compared with colds that lasted 2 to 3 weeks in the placebo 
group, colds in the carrageenan group were 20% to 40% shorter.
The effects of carrageenan within the quintile ranges of the dis-
tribution of common cold duration are shown in Table 2. The effect 
is calculated both as an absolute effect in days and as a relative ef-
fect in percentages. In the 4th quintile, the untreated mean com-
mon cold duration of 13.7 days is shortened on average by 3.8 days 
which corresponds to a 28% reduction in duration. In the 3rd quin-
tile, the untreated common cold duration of 8.8 days is shortened by 
1.3 days which corresponds to a 15% reduction. For the two lowest 
quintiles, there is no meaningful effect from carrageenan treatment.
The effect of carrageenan on the duration of colds was also 
analyzed as the risk of a person having a cold that lasted for over 
20 days, that is the unrecovered censored observations at the end 
of the follow- up. In the carrageenan group the risk of a cold lasting 
for over 20 days was 71% less than in the placebo group (Table 3). 
Among the patients administered placebo, 16.4% did not recover by 
the end of the 20- day follow- up, whereas just 4.7% of patients ad-
ministered carrageenan did not recover. This corresponds to a num-
ber needed to treat (NNT) of 8.6 (95% CI 5.2– 24).
The effect of iota- carrageenan on the recurrence of common 
cold symptoms is shown in Table 4. In all virus- positive patients, 
carrageenan reduced the recurrence of cold symptoms by 56%. 
The point estimates for the effect of carrageenan in the partici-
pants with coronavirus, influenza A virus, and rhinovirus are consis-
tent with the overall effect estimate. In all virus- positive patients, 
28.9% of placebo participants had a recurrence of cold symptoms 
after first recovering, compared with only 12.7% of carrageenan 
patients. This corresponds to a NNT of 6.2 (95% CI 3.8– 16).
4  |  DISCUSSION
Adults have on average two colds per year and young children six per 
year. Therefore, potential interventions to shorten and alleviate com-
mon cold symptoms are of great public health importance. Previously, 
zinc lozenges have been shown to shorten the common cold but the 
composition of the lozenges is crucial for effectiveness.29,39– 42 There 
is also evidence that regular intake of high- doses of vitamin C short-
ens colds that occur during the supplementation period,43– 45 and a 
recent randomized trial found that therapeutic vitamin C increased 
the recovery rate for outpatient cases of SARS- CoV- 2 infection.37 It 
seems that the effects of zinc lozenges and vitamin C for the com-
mon cold have been ignored not on the basis of evidence from rand-
omized trials, but because of prejudices.44– 47
Carrageenan is a more recent potential treatment for the com-
mon cold. Laboratory studies indicate that it has an effect on vari-
ous respiratory virus infections, including those caused by influenza 
viruses, coronavirus OC43, rhinoviruses, coxsackievirus, and SARS- 
CoV- 2,8– 17 but possibly not adenovirus.4,5 Although laboratory ev-
idence indicating that carrageenan can prevent virus infections 
traces back to the 1980s, clinical trials on the common cold have 
been carried out only since 2010.24– 27
A previous IPD meta- analysis of two carrageenan trials25,27 
calculated that colds were on average 1.9 days shorter in patients 
TA B L E  3 Effect	of	iota-	carrageenan	on	the	risk	of	the	common	
cold lasting over 20 days
Intervention Effect of carrageenan
Carrageenan Placebo RR (95% CI) p
Cold duration 
>20 days
6 21 0.29 (0.12– 0.70) .003
Total in group 126 128
RR, risk ratio of common cold lasting over 20 days comparing the iota- 
carrageenan versus placebo groups.
Viruses
Recurring symptoms/number 
of patients Effect of iota- carrageenan
Carrageenan Placebo RR (95% CI) p
All virusesa  16/126 37/128 0.44 (0.25– 0.75) .002
Coronavirus OC43 or 229E 8/45 19/43 0.40 (0.20– 0.82) .008
Influenza A 3/23 9/24 0.35 (0.10– 1.13) .057
Rhinovirus 6/70 16/80 0.43 (0.17– 1.04) .049
RR, risk ratio of recurrence of common cold symptoms comparing iota- carrageenan versus placebo 
groups.
aIn addition to the three virus groups listed, the “all viruses” group includes patients with influenza 
B, parainfluenza, respiratory syncytial virus, and metapneumovirus. A few patients had two or 
more viruses.
TA B L E  4 Effect	of	iota-	carrageenan	
on the risk of common cold symptoms 
recurring
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administered nasal carrageenan.28 However, the meta- analysis did 
not take account of the fact that there were censored data for 27 
patients which means that they did not recover by the end of the 
follow- up (Figure 1A). Therefore, the mean durations are undefined 
and the calculation of the difference in mean durations is inappropri-
ate. In addition, the meta- analysis28 did not consider the possibility 
that the effect of carrageenan might be heterogeneous.
In our IPD meta- analysis of the same two trials25,27 we used Cox 
regression and quantile regression, both of which take into account 
the censored observations. We found that there is strong evidence 
of a treatment effect for nasal iota- carrageenan when colds last over 
a week or so (Figures 1A and 2; Table 2). Our analysis did not demon-
strate an effect on shorter colds. The heterogeneity in the treatment 
effect indicates that the previously estimated 1.9- day reduction in 
common cold duration28 poorly captures the effects of nasal carra-
geenan (Figure 2).
In our analysis, we calculated that nasal carrageenan increased 
the recovery rate by 54% for all virus- positive participants during 
follow- up (Table 1). This effect is not as large as the approximately 
200% increase in recovery rate in five trials with zinc lozenges,40 but 
important nonetheless.
In quantile regression, we found that carrageenan shortened 
long colds by 15%– 28% (Table 2). These can be compared with the 
33% average decrease in common cold duration in seven trials with 
zinc lozenges,41 and the roughly 20% decrease in cold duration with 
high vitamin C doses.37,44,45,48 The benefit of nasal carrageenan was 
seen only on colds lasting over a week or so. However, a 28% short-
ening of 2- week colds is a much more important finding than a simi-
lar effect for short colds.
The effect of carrageenan on long colds was also analyzed as 
the risk of the cold lasting for over 20 days. Nasal carrageenan 
reduced the risk of such long colds by 71% (Table 3). On the 
basis of this outcome, one in every nine patients benefited from 
carrageenan.
The apparent benefit against long colds is relevant when con-
sidering two further trials on nasal iota- carrageenan. The first trial 
by Eccles administered carrageenan just for 4 days.24 The sec-
ond trial by Eccles also administered carrageenan for 4 days, yet 
patients were allowed to use it for longer; however, there are no 
data about how long the patients actually used carrageenan in that 
trial.26 Furthermore, the two trials followed the patients for just 7 
and 10 days, respectively, while the current analysis over 21 days 
indicates that the greatest benefits may appear only after 7 days 
(Figures 1A and 2). Nevertheless, even though ideally the interven-
tion and follow- up periods should have been longer, the two short- 
term trials also found that carrageenan was beneficial. In the first 
Eccles trial, the total symptom score over days 2– 4 was decreased 
by 26% (p = .046),24 and in the second, the total symptom score 
over days 1– 4 was decreased by 9% (p = .042).26 Reduction in the 
respiratory virus load has also been observed in the carrageenan 
participants.24– 28
We also found that carrageenan halved the recurrence of colds 
during the follow- up period (Table 4). On the basis of this finding, 
one in every six patients benefited from carrageenan. While it is not 
evident whether the recurrence of symptoms was caused by the 
same virus or by a new virus, halving the occurrence of new cold- 
type symptoms in such a large proportion of participants is a clin-
ically	 relevant	 finding.	Most	 recurrences	 occurred	 after	 cessation	
of treatment28 and therefore administration for longer than 7 days 
should be tested in further trials to ascertain whether recurrence 
may be further reduced.
The common cold is not a homogeneous entity. The majority 
of common cold symptoms are caused by several different virus 
types, but the distribution of viruses varies over time and location. 
In addition, some of the cold- type symptoms are caused by non- 
viral causes such as allergy and mechanical irritation. Nevertheless, 
as regards SARS- CoV- 2, the pattern of findings from carrageenan 
is particularly interesting. Our analysis gives strong direct evi-
dence that carrageenan is effective against two old coronaviruses 
OC43 or 229E by increasing the recovery rate by 139% and by de-
creasing the recurrence of cold symptoms by 60%. Even the old 
coronaviruses have caused severe acute respiratory infections.49 
Furthermore, the efficacy against rhinovirus and influenza A virus 
indicates that the effects are nonspecific. This does not necessarily 
mean that carrageenan is effective against SARS- CoV- 2; however, 
the non- specificity of carrageenan makes it highly plausible that 
carrageenan will also have an effect on COVID- 19. A very recent 
controlled trial found that iota- carrageenan prevented SARS- CoV- 2 
infection in health care workers who were exposed to COVID- 19 
patients,50 Finally, given the particular concern around long cases of 
COVID- 19,51,52 the proportionally greater effect of carrageenan on 
long infections seems particularly important.
The primary outcome in our analysis was self- reported recov-
ery from the common cold in the two included trials.25,27 Although 
some researchers may consider that a subjective outcome such as 
this one is suboptimal, it is the patient who decides whether to visit 
a physician to ask for a certificate for sick leave or to take time off 
work because of illness. Diagnosis of the common cold by virology 
is not feasible because of the large number of viruses and the vari-
ability in the disease states caused by the viruses. Given that pa-
tients are familiar with the common cold it seems a more reasonable 
approach to use self- diagnosis for clinical research.53 Furthermore, 
the FDA encourages patient- reported outcomes, because they are 
not biased by the interpretations of physicians or others.54
All four trials on nasal iota- carrageenan used 3– 4 daily dos-
es.24– 27 In further research, the dose– response should be inves-
tigated by testing a higher frequency of use to identify the level 
that leads to maximal effects. Similarly, the dose– response for 
the amount of carrageenan within the single nasal dose should 
be examined. Since most recurrences of cold symptoms occurred 
after cessation of treatment, longer administration should also be 
tested. It is also possible that the length of time between the onset 
of symptoms and the start of treatment has an impact on the effec-
tiveness. The two trials included in our meta- analysis specified that 
treatment was to be started within 36– 48 h of symptom onset,25,28 
whereas the corresponding time limit in zinc lozenge trials has 
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often been 24 h.42 Evidently, the effect of the time between the 
onset of symptoms and the start of carrageenan treatment on the 
size of the benefit should be investigated in further trials.
Laboratory studies have found that the combination of car-
rageenan with oseltamivir and zanamivir has synergistic effects 
against murine influenza.16,17 Similarly, it would seem reasonable to 
examine in a factorial setting the effects of combining carrageenan 
with zinc lozenges and/or vitamin C since they all seem to have dif-
ferent modes of effect.
In conclusion, we estimate that nasal iota- carrageenan may in-
crease the recovery rate from the common cold by about 50% and 
shorten the duration of long colds by about 30%. We did not find a 
beneficial effect on short colds. If able to be replicated, the findings 
of this study are important for future treatment options for coro-
navirus and influenza virus infections. Further research should be 
carried out to examine the effects of nasal iota- carrageenan on re-
spiratory virus infections in more detail.
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